Large-scale requirement of anti-hypertensive drugs and higher adoption of combination approaches drive the global oral controlled release drug delivery technology market
Oral control release drug delivery system provides high therapeutic efficiency, improved stability of drug, etc. As oral controlled release drug are cost effective, lowers the minimum dosage requirement and also lesser side effects are helping the sector in its lucrative growth. Prominent players in the sector include Bracco Group, Nemoto Kyorindo Co., Ltd., Sino Medical Device Technology Co., Ltd., Vivid Imaging, Guerbet Group, Medtron AG, Bayer HealthCare LLC, Ulrich GmbH & Co., Apollo RT Co. Ltd., Corium International Inc., Pfizer, Inc., Biogen, Glaxo Smith Kline, Novartis, Corium International, inc., Alza Corporation, etc. Development during the covd-19 pandemic and after it are helping the manufacturers to stabilise their position in the market.
There has been research regarding micro and nano-scale technologies in oral drug delivery. In the article published by ncbi.nlm.nih.gov, micro and nano scale technologies can create, control and measure micro environments. The nano and micro technology in drug discovery can be used in development of high throughput screening assays, miniaturization of therapeutic and diagnostic tools, tissue engineering and, oral drug delivery. These technologies help in sensing, recording and stimulating biological systems by fabrication techniques for optimised drug delivery.
3D printing technology has been an emerging technology on the design and manufacture of pharmaceutical oral formulation. As per the research Journal of Basic and Applied Sciences, 3D printing technique can be used to produce tailored doses of drug products at small scale. 3D printing can be an attractive research and development opportunity to improve drug formulation. With the help of 3D printing technology, the manufacturers are able to design and produce novel complex drug products and multiple active drug pharmaceutical ingredients into one dosage form with customised release trends.
In June 2020, Evonik launched a Resomer Precise custom and sophisticated technology to enable process validation of polymers to tight specifications in parental drugs. The platform enables pharmaceutical companies to control the release profile of parenteral drug products with a high level of accuracy and precision. Resomer precise aims to deliver significant value to pharmaceutical companies satisfying regulatory authorities.
The increase in generic drug consumption is driven by rising access to healthcare facilities and is fuelling the need for faster availability of drugs in oral solid dosages. This in turn fuels the need for application of controlled release technology, which could increase the availability of the drugs in reduced dosages.
Further, with many big drug makers establishing a local manufacturing presence across various regions, the adoption of controlled release technology is expected to witness a growing spiral in the coming years especially in countries such as Brazil, Argentina, Costa Rica and Mexico.
The combination of various technologies helps in rapidly overcoming problems associated with poorly soluble candidates. This is being aided through greater technology sharing through various conferences and symposiums where companies sharing similar thought processes meet and plan eventual outcomes. This helps in better pricing and rapid time to market for the otherwise unviable products in the short run. A higher adoption of combination approaches is expected to boost the global market for oral controlled release drug delivery technology.
Increasing approvals of modified and extended release oral dosage forms by PMDA is likely to drive the growth in revenue of the Japan oral controlled release drug delivery technology market. In the case of new approvals, high preference towards tablets and capsules has been observed, as formulation scientists find it easy to create formulations for clinical as well as therapeutic use.
Moreover, when compared to western countries such as the U.S. and Germany, Japan offers greater variety in the choice of oral solid dosage forms due to increased accessibility to local formulations.
Large-scale requirement of anti-hypertensive drugs are likely to boost the market growth to a great extent. The large-scale requirement of anti-hypertensive drugs is fuelling the need for more companies to set up plants deploying controlled release technologies. The requirement is more for technology adoption of OROS and SODAS. Indigenous development of pharmaceutical infrastructure is a very important factor expected to fuel revenue growth of the oral controlled release drug delivery technology market.
Diffusion and Dissolution are the most preferred controlled release systems, representing a lucrative market opportunity for manufacturers of oral controlled release drug delivery technologies
The Dissolution Controlled Release System segment dominated the global oral controlled release drug delivery technology market in terms of revenue in 2017, and the trend is projected to continue throughout the forecast period. Dissolution Controlled Release System is the most attractive segment, with an attractiveness index of 3.6 over the forecast period. This segment accounted for close to 45% value share in 2017 and is projected to hold about 50% share by 2027 end.
The Others segment, which includes upcoming technologies such as nanotechnology and other advanced matrix technologies is also growing at an exponential rate in terms of revenue in 2017 and the trend is projected to sustain throughout the forecast period. The Others segment is the most attractive segment, with a market attractiveness index of 0.6 over the forecast period.
Controlled Release Formulations – A common strategy to extend the product life cycle
Controlled Release is the most common strategy adopted by pharma giants across the globe to extend the product life cycle. Modified or controlled release formulations of pre-approved drugs are enjoying extended market exclusivity. The introduction of proprietary prescribed medicines in controlled release forms will help drive revenue growth of the global market.
Other release mechanisms include enteric release, such as those used in enteric softgel capsules, osmotically active release, effervescent and sublingual release. OROS (Johnson & Johnson and Alza Corporation) and SODAS (Elan Technologies) are the most commercialised technologies in the oral controlled release drug delivery technology market.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
- North America
- Latin America
- Western Europe
- Eastern Europe
By Drug Release System
- Diffusion Controlled Release System
- Dissolution Controlled Release System
- Osmotically Controlled Release System
- Dissolution & Diffusion Controlled Release System
- Ion Exchange Resins Controlled Release
- Hydro-dynamically Balanced Drug Delivery System
By Dosage Form
- Solid Dosage Forms